CRISPR Gene Editing Newsletter
Issue #62November 9, 20267 studies

A single infusion edited liver cells to slash LDL and triglycerides for 3 years in primates

Gene editing had a big week — and not just in the lab.

From a human liver biopsy confirming a successful base edit to a three-year primate study on cholesterol, the distance between bench and bedside got a little shorter.

One shot, three years of lower cholesterol 🧬

  • Researchers delivered a CRISPR adenine base editor — packaged in a lipid nanoparticle and aimed at a gene called ANGPTL3 — via a single intravenous infusion in nonhuman primates. The result: circulating ANGPTL3 protein dropped by more than 90%, and the reduction held for the full 3-year observation window.
  • In primate and mouse models of high cholesterol, that gene inactivation was associated with roughly 40–50% lower LDL cholesterol and 50–70% lower triglycerides — both major drivers of cardiovascular disease.
  • Critically, researchers screened approximately 3,000 candidate off-target sites in human liver cells and found no detectable off-target edits and no structural variants.

Why it matters: Most cholesterol drugs require daily or monthly dosing for life. A one-time infusion with durable, liver-specific effects — and a clean safety profile so far — is a meaningfully different proposition. A first-in-human trial in patients with refractory high-lipid conditions is now underway.

🔗 Nature Journal Article 🗓️ Nov 6

Key Findings

A liver biopsy confirmed base editing actually worked in a human 🔬

  • A patient with alpha-1 antitrypsin deficiency — a genetic liver and lung disease caused by a single mutation — received in vivo base editing therapy, and a subsequent liver biopsy directly confirmed that the target gene was corrected at the hepatic level.
  • This is the first reported clinical case where liver tissue was sampled post-treatment to verify the edit, moving beyond blood biomarkers alone.
💡 Direct biopsy confirmation raises the evidentiary bar for in vivo gene editing.
🥇 Top 1% journal 🔗 Journal of hepatology Case Reports 🗓️ Nov 2

A muscle-targeted virus fixed dystrophy in mice — while skipping the liver 🐭

  • Using a compact base editor packed into a single AAV vector with a muscle-tropic capsid called MyoAAV4, researchers restored dystrophin protein in the hearts and skeletal muscles of mice modeling Duchenne muscular dystrophy at a lower dose than conventional approaches.
  • A liver-detargeted capsid variant (MyoAAV4E-off) eliminated viral entry and editing in the liver entirely — addressing one of the field's persistent safety concerns around high-dose AAV.
💡 Liver-sparing muscle editing clears a key safety hurdle for dystrophy gene therapy.
🥈 Top 2% journal 🔗 The Journal of clinical investigation Journal Article 🗓️ Nov 2

Chromatin packaging affects base editors and prime editors very differently

  • In human cells, tightly packed heterochromatin — the "closed" regions of the genome — mostly blocked prime editors but left base editors unhindered, and in some cases base editors were actually more active in heterochromatin than in open chromatin regions.
  • The type and extent of editing byproducts from base editing also shifted depending on the epigenetic context of the target sequence, which has direct implications for how editing safety is assessed.
💡 Where a gene sits in the genome shapes editing outcomes as much as the editor itself.
🔗 Molecular cell Journal Article 🗓️ Nov 3

Prime editing stacked multiple disease-resistance traits in tomato in one generation 🍅

  • Using three optimized prime editors, researchers precisely recreated a pepper-derived disease-resistance deletion in tomato and separately introduced mutations that conferred resistance to two different bacterial pathogens — Xanthomonas and Pseudomonas syringae.
  • A multiplex prime editing system combined these resistance alleles within a single generation, and the traits were stably inherited and maintained under elevated temperature conditions.
💡 Multiplex prime editing compresses years of resistance breeding into a single crop generation.
🔗 The Plant cell Journal Article 🗓️ Nov 5

Supercharging NK cells with CRISPR may help clear HIV reservoirs

  • Using a CRISPR activation approach — which turns genes up rather than cutting them out — researchers simultaneously boosted expression of IL-15 and its receptor in primary natural killer cells without altering the underlying DNA sequence.
  • In lab co-culture experiments with HIV-positive T-cell lines, these enhanced NK cells showed increased target cell elimination and higher secretion of an immune-signaling protein compared to unmodified cells.
💡 Non-cutting CRISPR activation offers a reversible path to stronger HIV-targeting immune cells.
🎖️ Top 10% journal 🔗 Journal of leukocyte biology Journal Article 🗓️ Nov 5

A $3 sealed-tube test detected two STIs from whole blood in 30 minutes 💉

  • A microfluidic chip integrating recombinase amplification, light-triggered CRISPR activation, and dual fluorescence readout simultaneously detected HIV and syphilis-causing bacteria directly from whole blood, with no external lab equipment needed.
  • In 51 clinical samples, the fluorescence readout hit 100% sensitivity and specificity; per-reaction reagent cost was estimated at USD 3.21 using bulk-purchased components.
💡 A sealed, sub-$4 CRISPR chip matches lab PCR accuracy for two major STIs simultaneously.
🎖️ Top 10% journal 🔗 ACS sensors Journal Article 🗓️ Nov 4

Implications

Base editing is quietly moving from animal models into human tissue confirmation — a shift that changes what counts as evidence. The open question: whether the clean off-target profiles seen in controlled primate and cell-line studies will hold across the genetic diversity of real patient populations at scale.

Studies in this issue

Primary sources used for this newsletter.